EGFR and non-small cell lung carcinoma: For example, somatic mutations in the epidermal growth factor receptor (EGFR) gene predict which patients with non-small-cell lung carcinoma (NSCLC) will likely respond to gefitinib or erlotinib treatment [1, 3, 9].